Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Polycythemia Vera 1Myeloproliferative Disorders 1

Interventions

fludarabine phosphate 18Whole-Body Irradiation 12Peripheral Blood Stem Cell Transplantation 12Mycophenolic Acid 11ruxolitinib 10Busulfan 10Tacrolimus 9Cyclophosphamide 9fludarabine 6Methotrexate 5Melphalan 5Cyclosporine 5Hydroxyurea 4Antilymphocyte Serum 4pomalidomide 3givinostat hydrochloride 3givinostat 3Stem Cell Transplantation 3Prednisone 3Lenalidomide 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3thymoglobulin 2peginterferon alfa-2a 2merphos 2Surveys and Questionnaires 2Radiotherapy 2Imatinib Mesylate 2Etoposide 2Dasatinib 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Polycythemia Vera × anagrelide × Clear all
NCT01243944 2019-03-06

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Incyte Corporation

Phase 3 Completed
222 enrolled 21 charts
Myeloid

Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon âš¡